778 related articles for article (PubMed ID: 28835229)
1. Does dapagliflozin regress left ventricular hypertrophy in patients with type 2 diabetes? A prospective, double-blind, randomised, placebo-controlled study.
Brown AJM; Lang C; McCrimmon R; Struthers A
BMC Cardiovasc Disord; 2017 Aug; 17(1):229. PubMed ID: 28835229
[TBL] [Abstract][Full Text] [Related]
2. Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.
Verma S; Mazer CD; Yan AT; Mason T; Garg V; Teoh H; Zuo F; Quan A; Farkouh ME; Fitchett DH; Goodman SG; Goldenberg RM; Al-Omran M; Gilbert RE; Bhatt DL; Leiter LA; Jüni P; Zinman B; Connelly KA
Circulation; 2019 Nov; 140(21):1693-1702. PubMed ID: 31434508
[TBL] [Abstract][Full Text] [Related]
3. Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design.
Singh JS; Fathi A; Vickneson K; Mordi I; Mohan M; Houston JG; Pearson ER; Struthers AD; Lang CC
Cardiovasc Diabetol; 2016 Jul; 15():97. PubMed ID: 27422625
[TBL] [Abstract][Full Text] [Related]
4. Renal and Cardiovascular Effects of sodium-glucose cotransporter 2 (SGLT2) inhibition in combination with loop Diuretics in diabetic patients with Chronic Heart Failure (RECEDE-CHF): protocol for a randomised controlled double-blind cross-over trial.
Mordi NA; Mordi IR; Singh JS; Baig F; Choy AM; McCrimmon RJ; Struthers AD; Lang CC
BMJ Open; 2017 Oct; 7(10):e018097. PubMed ID: 29042392
[TBL] [Abstract][Full Text] [Related]
5. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
Frías JP; Guja C; Hardy E; Ahmed A; Dong F; Öhman P; Jabbour SA
Lancet Diabetes Endocrinol; 2016 Dec; 4(12):1004-1016. PubMed ID: 27651331
[TBL] [Abstract][Full Text] [Related]
6. A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial.
Brown AJM; Gandy S; McCrimmon R; Houston JG; Struthers AD; Lang CC
Eur Heart J; 2020 Sep; 41(36):3421-3432. PubMed ID: 32578850
[TBL] [Abstract][Full Text] [Related]
7. Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure.
Soga F; Tanaka H; Tatsumi K; Mochizuki Y; Sano H; Toki H; Matsumoto K; Shite J; Takaoka H; Doi T; Hirata KI
Cardiovasc Diabetol; 2018 Oct; 17(1):132. PubMed ID: 30296931
[TBL] [Abstract][Full Text] [Related]
8. Effects of empagliflozin in different phases of diabetes mellitus-related cardiomyopathy: a prospective observational study.
Oka S; Kai T; Hoshino K; Watanabe K; Nakamura J; Abe M; Watanabe A
BMC Cardiovasc Disord; 2021 Apr; 21(1):217. PubMed ID: 33926386
[TBL] [Abstract][Full Text] [Related]
9. Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study.
Rau M; Thiele K; Hartmann NK; Schuh A; Altiok E; Möllmann J; Keszei AP; Böhm M; Marx N; Lehrke M
Cardiovasc Diabetol; 2021 Jan; 20(1):6. PubMed ID: 33413355
[TBL] [Abstract][Full Text] [Related]
10. Rationale and Design of the EMPA-TROPISM Trial (ATRU-4): Are the "Cardiac Benefits" of Empagliflozin Independent of its Hypoglycemic Activity?
Santos-Gallego CG; Garcia-Ropero A; Mancini D; Pinney SP; Contreras JP; Fergus I; Abascal V; Moreno P; Atallah-Lajam F; Tamler R; Lala A; Sanz J; Fuster V; Badimon JJ
Cardiovasc Drugs Ther; 2019 Feb; 33(1):87-95. PubMed ID: 30675708
[TBL] [Abstract][Full Text] [Related]
11. Dapagliflozin reduces systemic inflammation in patients with type 2 diabetes without known heart failure.
Wang DD; Naumova AV; Isquith D; Sapp J; Huynh KA; Tucker I; Balu N; Voronyuk A; Chu B; Ordovas K; Maynard C; Tian R; Zhao XQ; Kim F
Cardiovasc Diabetol; 2024 Jun; 23(1):197. PubMed ID: 38849829
[TBL] [Abstract][Full Text] [Related]
12. Positive effect of dapagliflozin on left ventricular longitudinal function for type 2 diabetic mellitus patients with chronic heart failure.
Tanaka H; Soga F; Tatsumi K; Mochizuki Y; Sano H; Toki H; Matsumoto K; Shite J; Takaoka H; Doi T; Hirata KI
Cardiovasc Diabetol; 2020 Jan; 19(1):6. PubMed ID: 31910853
[TBL] [Abstract][Full Text] [Related]
13. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.
Tanaka A; Shimabukuro M; Okada Y; Taguchi I; Yamaoka-Tojo M; Tomiyama H; Teragawa H; Sugiyama S; Yoshida H; Sato Y; Kawaguchi A; Ikehara Y; Machii N; Maruhashi T; Shima KR; Takamura T; Matsuzawa Y; Kimura K; Sakuma M; Oyama JI; Inoue T; Higashi Y; Ueda S; Node K;
Cardiovasc Diabetol; 2017 Apr; 16(1):48. PubMed ID: 28403850
[TBL] [Abstract][Full Text] [Related]
14. Rationale and design of a multicentre, randomized, placebo-controlled trial of mirabegron, a Beta3-adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease Beta3-left ventricular hypertrophy (Beta3-LVH).
Pouleur AC; Anker S; Brito D; Brosteanu O; Hasenclever D; Casadei B; Edelmann F; Filippatos G; Gruson D; Ikonomidis I; Lhommel R; Mahmod M; Neubauer S; Persu A; Gerber BL; Piechnik S; Pieske B; Pieske-Kraigher E; Pinto F; Ponikowski P; Senni M; Trochu JN; Van Overstraeten N; Wachter R; Balligand JL
ESC Heart Fail; 2018 Oct; 5(5):830-841. PubMed ID: 29932311
[TBL] [Abstract][Full Text] [Related]
15. Dapagliflozin's Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension.
Cefalu WT; Leiter LA; de Bruin TW; Gause-Nilsson I; Sugg J; Parikh SJ
Diabetes Care; 2015 Jul; 38(7):1218-27. PubMed ID: 25852208
[TBL] [Abstract][Full Text] [Related]
16. Effect of etelcalcetide on cardiac hypertrophy in hemodialysis patients: a randomized controlled trial (ETECAR-HD).
Dörr K; Kammer M; Reindl-Schwaighofer R; Lorenz M; Loewe C; Marculescu R; Erben R; Oberbauer R
Trials; 2019 Oct; 20(1):601. PubMed ID: 31651370
[TBL] [Abstract][Full Text] [Related]
17. The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial.
Wiviott SD; Raz I; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Silverman MG; Bansilal S; Bhatt DL; Leiter LA; McGuire DK; Wilding JP; Gause-Nilsson IA; Langkilde AM; Johansson PA; Sabatine MS
Am Heart J; 2018 Jun; 200():83-89. PubMed ID: 29898853
[TBL] [Abstract][Full Text] [Related]
18. Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes.
Trujillo JM; Nuffer WA
Pharmacotherapy; 2017 Apr; 37(4):481-491. PubMed ID: 28102030
[TBL] [Abstract][Full Text] [Related]
19. ELUCIDATE Trial: A Single-Center Randomized Controlled Study.
Lin JL; Liu SC; Liu TF; Chuang SM; Huang CT; Chen YJ; Lee CC; Chien MN; Hou CJ; Yeh HI; Chiang CE; Hung CL
J Am Heart Assoc; 2024 May; 13(9):e033832. PubMed ID: 38639353
[TBL] [Abstract][Full Text] [Related]
20. Can we go beyond surrogates?
Drexler A
J Diabetes; 2017 Nov; 9(11):976-977. PubMed ID: 28692750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
